Neural stem cells (NSCs) have been considered as potential therapy in Alzheimer's disease (AD) but their use is hampered by the poor survival of grafted cells. Supply of neurotrophic factors to the grafted cells has been proposed as a way to augment survival of the stem cells. In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD. We grafted murine NSCs into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9 months post grafting. Compared to vehicle-treated non-tg mice, in the vehicle-treated APP tg mice there was considerable reduction in the survival of the grafted NSCs. Whereas, CBL treatment enhanced the survival of NSCs in both non-tg and APP tg with the majority of the surviving NSCs remaining as neuroblasts. The NSCs of the CBL treated mice displayed reduced numbers of caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity. These results suggest that CBL might protect grafted NSCs and as such be a potential adjuvant therapy when combined with grafting.
Introduction
The neurogenerative process in patients with Alzheimer's disease (AD) is characterized by synaptic loss (Overk and Masliah, 2014) and loss of cholinergic, glutaminergic and GABA-ergic neurons (DeKosky et al., 1996; Masliah, 1995 Masliah, , 2001 Masliah et al., 2006; Scheff et al., 1990; Terry et al., 1991; Trojanowski et al., 1995) . In addition, more recent studies suggest that alterations in adult neurogenesis in the hippocampus might also contribute to the neurodegenerative process in AD (Dong et al., 2004) . There is some controversy over whether neurogenesis is increased (Jin et al., 2004) or decreased (Boekhoorn et al., 2006; Li et al., 2008) in AD. Recent studies suggest that apparent increases in neurogenesis in AD patients may be related to glial and vasculature-associated changes (Boekhoorn et al., 2006) . Studies in a number of animal models of Familial AD have shown that neurogenesis is reduced (Dong et al., 2004; Donovan et al., 2006; Haughey et al., 2002; Rockenstein et al., 2007) .
The mechanisms of neurodegeneration in AD are not completely clear, however progressive accumulation of amyloid beta (Aβ) with the formation of oligomers appears to trigger a complex cascade of events that includes activation of several kinases including glycogen synthetase kinase (GSK3β) and cyclin dependent kinase-5 (CDK5) Engmann and Giese, 2009; Shukla et al., 2012) leading to aberrant post-transcriptional modification of the microtubule binding protein-Tau (Gong and Iqbal, 2008) . Moreover, other studies suggest that deficient transport or expression of neurotrophic factors (NTF) (e.g., nerve growth factor [NGF], brain derived neurotrophic factor [BDNF] ) and their receptors might be involved (Peng et al., 2005; Schindowski et al., 2008; Scott et al., 1995) . For this reason, experimental therapies for AD involve reducing the Aβ load, blocking kinases such as GSK3β and CDK5, reducing Tau and replacement therapies with NTFs (Blurton-Jones et al., 2009; Nagahara et al., 2009; Tuszynski, 2007; Tuszynski et al., 2005) .
However, given the advanced clinical stage at which several patients with AD present, alternative therapies are under consideration including replacement therapy with neuronal stem cell grafts. For example, previous studies have shown that neural stem cells (NSC) transferred into the hippocampus of AD transgenic (tg) models improve cognition via BDNF (Nagahara et al., 2009 (Nagahara et al., , 2013 and reduce Tau and reelin accumulation in aged Ts65DN model of Down's syndrome (Kern et al., 2011) . Moreover, transplantation of NSC derived from induced pluripotent stem cells (iPSC) restore memory in amyloid precursor protein (APP) tg (Fujiwara et al., 2013) and APP/Presenilin-1 (PS1) mice (Zhang et al., 2014a) supporting the notion that treatment with NSCs might be of useful in AD patients. However, a potential problem is the reduced viability of the transplanted cells given the noxious microenvironment in the brain of patients with AD. For example, we have recently shown that under baseline conditions NSC display reduced viability when transplanted into the brains of APP mice, however when these cells are modified to express the Aβ degrading enzyme, neprilysin, the stem cells are more prone to survive (Blurton-Jones et al., 2014) . Therefore, adjuvant therapies that enhance survival of grafted stem cells might be important.
Among them, we have considered the potential of combining stem cells with Cerebrolysin™ (CBL) a peptide mixture with neurotrophic-like properties that improves cognition in patients with mild to moderate AD (Alvarez et al., 2006 Gauthier, 2009, 2010; Ruther et al., 1994 Ruther et al., , 2000 . CBL has been shown to be protective in experimental models of excitotoxicity (Veinbergs et al., 2000) and stroke (Onishchenko et al., 2008; Ren et al., 2007; Zhang et al., 2010) . In addition, CBL is neurotrophic in APP tg models of AD by promoting synaptic formation and neurogenesis (Blanchard et al., 2010a,b; Chohan et al., 2011; Rockenstein et al., 2002 Rockenstein et al., , 2003 Rockenstein et al., , 2005 Rockenstein et al., , 2007 . The protective effects of CBL in AD-like models involve different mechanisms including regulation of GSK3β and CDK5 signaling, control of APP metabolism and antiapoptotic effects mediated by expression of endogenous neurotrophic factors (Ubhi et al., 2013) . In this context, the main objective of this study was to investigate whether CBL is capable of enhancing the survival of transplanted NSCs. We found NSC survival progressively declined with age in APP tg mice when compared to controls and that adjuvant therapy with CBL enhanced survival of the BrdU tagged grafted NSC. This study supports the notion that CBL might be a potentially useful adjuvant therapy in combination with NSCs.
Materials and methods
Preparation and CBL testing in mouse cortical neural stem cells Briefly, as previously described (Crews et al., 2011; Desplats et al., 2012) , mouse cortical NSCs were obtained from Millipore. The NSCs were grown on F12/DMEM basal media supplemented with B27 and were kept in proliferative status without induction of neuronal differentiation. Cells were labeled 48 h prior to grafting into the mouse by infection with lentiviral constructs containing the GFP coding sequence at a MOI = 50. Additional pulse labeling with BrdU was carried out 24 h prior to grafting. For in vitro experiments, NSCs were treated with vehicle alone or CBL (5%) and grown in 35 mm dishes and in 6 well plates with a coverslip in the bottom for subsequent ELISA and immunocytochemical studies respectively.
Generation of APP Tg Mice, grafting and Cerebrolysin treatment
For these experiments, hAPP tg mice expressing mutated (Swedish K670M/N671L, London V717I) human(h) APP751 under the control of the mouse (m) Thy-1 promoter (mThy1-hAPP751) (line 41) (Rockenstein et al., 2001) were used. These mice have been extensively characterized (Crews et al., , 2011 Havas et al., 2011; Rockenstein et al., 2011; Spencer et al., 2008) and we have previously shown that these mice display loss of synaptic contacts, defects in neurogenesis, high levels of Aβ 1-42 production, early amyloid deposition and behavioral deficits (Rockenstein et al., 2003 (Rockenstein et al., , 2007 . Genomic DNA was extracted from tail biopsies and analyzed by PCR amplification, as described previously (Rockenstein et al., 1995) . Transgenic lines were maintained by crossing heterozygous tg mice with non-transgenic (non tg) C57BL/6 × DBA/2 F1 breeders. All mice were heterozygous with respect to the transgene.
A total of 128 mice (3 month old) were included in this study (n = 64 non-tg and n = 64 APP tg mice) that were divided into groups of n = 32 corresponding to the post graft time points at which they were analyzed (1, 3, 6 and 9 months). All animals received bilateral stereotaxical injections of the green fluorescent protein (GFP) and BrdU tagged NSC suspension containing 5 × 10 4 cells/μl. Each of the groups (4 groups × n = 32 per time point) included n = 16 non-tg (n = 8 vehicle and n = 8 CBL) and n = 16 APP tg (n = 8 vehicle and n = 8 CBL) mice. CBL was provided by EVER Pharma in pre-prepared ampoules, each milliliter of CBL contains 215.2 mg of the active CBL concentrate in an aqueous solution (EBEWENeuroPharmaGmbH, 2009) . Mass spectrometry analysis of CBL has shown that it is comprised of amino acids (80%) and small (b 10 Da) peptides (20%) and previous work had shown that this small peptides mimic the effect of neurotrophic factors including ciliary neurotrophic factor (CNTF), fibroblast growth factor 2 (FGF2) and insulin-like growth factor (IGF) (Chen et al., 2007) . Mice were injected daily for the duration of the experiment with saline alone or CBL (i.p., 5 ml/kg, CBL Batch #92382008) for a total of 1, 3, 6 or 9 months. By the end of the experiment for each corresponding group mice were 4, 6, 9 and 12 months old.
All experiments described were approved by the animal subjects committee at the University of California at San Diego (UCSD) and were performed according to NIH guidelines for animal use.
Tissue processing
In accordance with NIH guidelines for the humane treatment of animals, mice were anesthetized with chloral hydrate and flush-perfused transcardially with 0.9% saline. Brains were removed and divided sagitally. The left hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) at 4°C for 48 h and sectioned at 40 μm with a Vibratome 2000 (Leica, Germany), while the right hemibrain was snap frozen and stored at − 70°C.
Immunohistochemical analysis
Briefly, as previously described (Blurton-Jones et al., 2014; Rockenstein et al., 2007) , blind-coded 40 μm thick vibratome sections were immunolabeled with mouse monoclonal antibodies against BrdU (1:500, Millipore), PCNA (1:500, Millipore), GFAP (1:500, Milllipore), NeuN (1:500, Millipore), doublecortin (DCX) (1:500, Millipore), Ki-67 (1:100, Santa Cruz), activated caspase-3 (1:1000, Cell Signal), BDNF (1:250, Abcam), NT4 (1:100, Pierce) and furin (1:100, Pierce) followed by horse anti mouse biotinylated secondary antibody and developed with diaminobenzidine and imaged with an Olympus OX54 digital photomicroscope. An additional series of sections were incubated with antibodies against the dendritic marker MAP2 (1:500, Milllipore) and Aβ (1:500, 82E1, IBL). After overnight incubation with the primary antibodies, sections were incubated with FITC-conjugated horse anti-mouse IgG secondary antibody (1:75, Vector Laboratories, Burlingame, CA), transferred to SuperFrost slides (Fisher Scientific, Tustin, CA) and mounted under glass coverslips with anti-fading media (Vector). Moreover, double immunolabeling experiments were performed with the following combinations of antibodies: 1) anti-BrdU and anti-GFP; 2) anti-NeuN and anti-GFP; 3) anti-GFAP and anti-GFP; 4) anti-olig-2 and anti-GFP; 5) anti-BDNF and anti-GFP and 6) anti-Furin and anti-GFP. The BrdU, NeuN, GFAP, olig-2, BDNF and furin were detected with Tyramide Red (NEN) while the GFP was detected via amplification with FITC (green channel). All sections were processed under the same standardized conditions. The immunolabeled sections were imaged with the laser-scanning confocal microscope (LSCM, MRC1024, BioRad, Hercules, CA) and analyzed as previously described (Rockenstein et al., 2003) . Briefly, for each section a total of 8 images at 630× were analyzed. For each image a threshold was set utilizing the Image Quant system, the threshold was set within a dynamic range that was consistent for all cases. The levels of pixel intensity or optical density for the area were ascertained with the measure tool of the system. An adjacent un-stained area was used as background to correct against. Area of images analyzed was on average 1024 by 1024 pixels. This area included on average at least 4-5 neurons that were analyzed. The average integrated pixels of optical density for all neurons within that area were estimated and then averaged by the 16 images captured. The average was corrected to the background and expressed as an overall mean by mouse per group. To confirm the specificity of primary antibodies, control experiments were performed where sections were incubated overnight in the absence of primary antibody (deleted) or with preimmune serum or with primary antibody alone.
Unbiased stereology
Stereological methods were used to estimate the number of BrdU immunoreactive cells utilizing an optical fractionator unbiased sampling design (Rockenstein et al., 2007) . A total of 4 alternating sections separated by approximately 250 μm containing the hippocampus were outlined using a 4× objective attached to an Olympus BX51 microscope. Anatomical nomenclature was based on Paxinos and Franklin (2001) . A systematic sampling of the outlined areas was made from a random starting point using StereoInvestigator 8.21.1 software (Micro-BrightField, Cochester, VT). Counts were taken at predetermined intervals (x = 152, y = 152), and a counting frame (70 × 70 μm = 4900 μm 2 ) was superimposed on the live image of the tissue sections. Sections were analyzed using a 60× 1.4 PlanApo oil-immersion objective with a 1.4 numerical aperture. Section thickness was determined by focusing on the top of the section, zeroing the z-axis and focusing on the bottom of the section. Average section thickness was 18 μm. The dissector height was set at 12 μm. This allowed for a 2-μm top guard zone and at least a 2-μm bottom guard zone. The forbidden zones were never included in the cell counting. Immunoreactive neurons were only counted if the first recognizable profile came into focus within the counting frame. This method allowed for a uniform, systematic, and random design. Differences in stereologic counts were evaluated using the Mann-Whitney test for median differences (GraphPad Prism 4.0c for Macintosh, San Diego, CA). The level of statistical significance was set at p-value b 0.05.
Determination of NTF protein content by ELISA
As previously described (Ubhi et al., 2013) , levels of Furin and BDNF were determined in whole brain homogenates by ELISA according to the supplier's protocol (Promega, Madison, WI). The samples were sonicated in a homogenization buffer (20 mM Tris, pH 8, 137 mM NaCl, 1% Nonidet P-40, 1.7 μg/ml phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1 μg/ml leupeptin and 0.5 mM sodium vanadate) at a tissue concentration of 30 μl/mg. An additional control ELISA was performed on whole brain homogenates from non tg mice that had been treated with an amino acid control for CBL.
Statistical analysis
Statistical analysis was performed with the Prism Graph path software package (La Jolla, CA). All results are expressed as mean plus minus SEM. Differences among multiple groups were assessed by one-way ANOVA with post-hoc Dunnett's when comparing to the control group, comparisons among the treatment groups was performed with the Tukey posthoc test. Comparisons between 2 groups were assessed using the two-tailed unpaired Student's t-test.
Results
The reduced survival of grafted NSCs in the brains of APP tg mice is improved by Cerebrolysin treatment
To investigate the survival of grafted cells in APP tg mice, cortical derived mouse NSCs labeled with BrdU and GFP were injected into the hippocampus and mice were analyzed 1, 3, 6 and 9 m post transplantation. Immunocytochemical analysis with an antibody against BrdU showed that the transplanted cells distributed mostly around the CA1 region, the dentate gyrus and the sub-granular zone of the hippocampus (Figs. 1A-C). After 1 month, in the vehicle-treated non-tg mice an average of 13,100 per unit area were found, which was equivalent to approximately to 13.5% of the grafted cells (Figs. 1A, D) . After 3 months there was a decline to 5.8% that was stabilized after 6 and 9 months post transplant (6.5%) (Figs. 1B, D) . When compared to the non-tg vehicle control group, in the APP tg mice there was a significant reduction in the survival of the grafted cells 1 m post-graft (5100 cells or 5.4%) (Figs. 1B, D) . At the later time points only few grafted cells (less than the equivalent to 1%) were found in the vehicle APP tg group (Figs. 1C, D) . In the non-tg mice, the numbers of BrdU positive NSCs were similar in the vehicle and CBL treated mice, however after 3, 6 and 9 months survival was higher (14%) in the CBL treated mice compared to vehicle (5.8%) (Fig.  1D) . After 1 month in the CBL treated APP tg mice the numbers of BrdU positive NSCs (18,900 or 24%) were above the non-tg groups and the vehicle treated APP mice (Figs. 1A, D) . After 3, 6 and 9 months of the transplant the numbers of surviving NSCs were comparable to the non-tg CBL group (12.1%) and above the vehicle-treated APP tg (less than 1%) (Figs. 1B-D) . To further corroborate that the BrdU detected cells were the grafted cells, double labeling experiments were performed with antibodies against BrdU and GFP. By confocal microscopy it was observed that the great majority of the GFP positive cells also displayed BrdU reactivity (Figs. 1E, F) . These results support the notion that grafted NSC display poor survival in the brains of APP tg mice and that adjuvant treatment with CBL reverts this effect.
Effects of Cerebrolysin and NSC grafting on AD-like neuropathology and endogenous neurogenesis in APP tg mice
To confirm the presence of AD-like neuropathology in the brains of APP tg mice and to evaluate the impact of the combined effects of NSC grafting and CBL treatment sections were immunolabeled with antibodies against Aβ and GFAP.
As expected compared to the non-tg group the vehicletreated APP tg mice displayed extensive Aβ deposition in the neocortex and hippocampus that increased over time D) . In contrast, the CBL treated APP tg mice displayed a reduced amyloid deposition that was more prominent 6 and 9 months post-graft and CBL treatment (Figs. 2C upper panels, D) . With the antibody against GFAP, in both groups of APP tg mice there was astrogliosis more prominent in the hippocampus than in the neocortex (Figs. 2A-C lower panels) . Besides the expected astrogliosis along the injection site no prominent glial reaction was observed as result of the placement of the NSC graft (Figs. 2A-C lower panels) . Next we analyzed the effects on neurodegeneration, as we have previously shown that APP tg mice display age related synapto-dendritic loss in the dentate gyrus of the hippocampus (Rockenstein et al., 2002) . For this purpose sections were immunolabeled with an antibody against MAP2 and analyzed by confocal microscopy (Fig. 3A) . Analysis at 1 month after grafting showed that non-tg and APP tg mice displayed comparable levels of MAP2 immunoreactivity in the molecular layer of the dentate gyrus, although compared to the vehicle, the CBL treated group had slightly higher levels of MAP2 (Figs. 3A, B) . However, 3, 6 and 9 m post-grafting the vehicle-treated APP tg mice displayed a significant reduction in the % area of the neuropil covered by MAP2 immunoreactive dendrites (Figs. 3A, B) . Compared to vehicle group, grafted APP tg mice displayed levels of MAP2 comparable to the non-tg mice (Fig. 3B) .
We have previously shown that in addition to the synaptodendritic damage, APP tg mice display reduced neurogenesis in the hippocampus (Rockenstein et al., 2007) . To evaluate the combined effects of NSC grafting and CBL treatment on endogenous neurogenesis, sections were immunostained with an antibody against double-cortin DCX (Fig. 3C) . Analysis at 1 month after grafting showed that compared to vehicle treated non-tg, the APP tg mice displayed a 47% reduction in the number of DCX positive neuroblasts in the subgranular zone of the hippocampus (Figs. 3C, D) , in contrast grafted APP tg mice treated with CBL displayed DCX levels comparable to the un-treated non-tg mice (Fig. 3D) . After 3, 6 and 9 m post-grafting the vehicle treated APP tg mice displayed further reduction in the numbers of DCX immunoreactive cells (Figs. 3C, D) . A similar trend was observed 3 months after grafting in the non-tg mice and in the CBL treated APP tg (Figs. 3C, D) . However, at 6 and 9 months numbers of DCX immunoreactive cells leveled (Fig. 3C) . Taken together, these studies suggest that the combined effects of enhanced survival of NSC with CBL reduce neurodegeneration in the hippocampus of APP tg mice by ameliorating the degeneration of granular cells and endogenous neuroblasts in the hippocampal dentate gyrus.
Cerebrolysin treatment promotes survival of grafted NSC with no evidence of tumoral proliferation
Given that a subpopulation of grafted NSCs distributes in the dentate gyrus and that there is reduced neurodegeneration and increased endogenous neurogenesis in the granular zone, it is possible that CBL might promote differentiation and integration of grafted NSCs into the hippocampus. To investigate this possibility sections were double labeled with antibodies against a mature neuronal marker (NeuN, red) and GFP (to enhance the visualization of the tagged grafted NSCs). Consistent with the BrdU immunocytochemistry studies (Figs. 1A-C) , GFP positive cells were identified in the sub-granular zone of the dentate gyrus and in between granular cells (Fig. 4A) . At 1 m post grafting, compared to vehicle treated non-tg mice, the vehicle treated APP tg mice displayed a 82% reduction in the numbers of surviving GFP positive NSCs (Figs. 4A, B) . In contrast, CBL treatment resulted in an increased number of GFP positive NSCs in the dentate gyrus of non-tg and APP tg mice above the baseline of the controls (Figs. 4A, B) . At 3, 6 and 9 months post-grafting there was a mild decline in GFP positive cells in the vehicle treated non-tg mice (Fig. 4A) , while in the vehicle treated APP tg mice the numbers remained very low (Figs. 4A, B) . Whereas the CBL treated non-tg and APP tg mice continued to show the presence of GFP positive NSCs above baseline controls (Figs. 4A, B) . In all four experimental groups, closer analysis of the immunolabeled sections showed that none of the GFP positive cells were NeuN positive, neither the GFP positive NSCs displayed the presence of neuritic extensions or integration into the dentate gyrus (Fig. 4A arrowheads) . Additional double labeling analysis was performed with antibodies against the astroglial marker GFAP (red channel) and GFP (green channel) (Fig. 4C) . About 2% of the GFP positive NSCs displayed GFAP immunoreactivity and a glial like morphology (Fig. 4C) . Compared to non-tg mice in the APP tg mice at 3 months post grafting there was an increase in the % of cells displayed GFP and GFAP immunostaining (Figs. 4C, D) . No significant effects were detected following CBL treatment (Fig. 4D) .
These findings support the notion that CBL might act by enhancing the survival (or proliferation) of grafted NSCs rather than by promoting differentiation. Based on the initial studies showing that starting at 3 months post grafting CBL supports the viability of NSC (Fig. 1B) and to further evaluate the effects of CBL on NSC survival and proliferation sections of mice at the 9 month post-graft were immunolabeled with antibodies against activated caspase-3 and PCNA and stained with a modified version of the TUNEL technique (Fig. 5A) . Compared to vehicle treated non-tg mice, the CBL treated mice showed reduced active capase-3 and TUNEL positive NSCs (Fig. 5B) . In contrast, vehicle treated APP tg mice displayed higher numbers of active capase-3 and TUNEL positive NSCs (Figs. 5B, C) , this effect was reversed by CBL treatment (Figs. 5B, C) . Occasional PCNA immunoreactivity was detected in the grafted NSCs; no significant differences were detected among the four groups (Fig. 5D) . Likewise, analysis with an antibody against the proliferation markerKi-67, at low power no evidence of tumoral proliferation was noted (Fig. 6A) , at higher magnification occasional Ki-67 positive cells were noted in the hippocampus (Fig. 6B arrows) , treatment with CBL did not reveal an increase in proliferation of NPCs in the grafted area at any of the time points including 9 months post transplantation (Figs. 6B and C). Together these results support the possibility that CBL might enhance the survival of grafted NSCs.
Adjuvant therapy with Cerebrolysin results in increased BDNF and furin levels in grafted NSCs
Since it has been previously shown that CBL increases the conversion of pro-NGF to mature NGF via furin (Ubhi et al., (Fig. 5E ). This study showed that both in non-tg and tg mice levels of BDNF and furin immunostaining were increased in the NSCs of CBL treated mice (Figs. 5E, F, H). No differences were detected for NT4 (Figs. 5E, G) . To further confirm that the grafted NSCs were producing BDNF and furin double labeling with GFP was performed (Figs. 5I,  K) . These studies showed that in the saline treated animals an average of 4% (Figs. 5I, J) and 10% (Figs. 5K, L) This study showed that CBL increased BrdU levels (Figs. 7A,  B) and decreased TUNEL positive cells at 4 and 8 DIV (Figs. 7C, D) . At 4 and 8 DIV the % of MAP2 positive cells increased but no differences were detected between the vehicle and CBL groups (Figs. 7E, F) . Moreover, analysis of the levels of BDNF (Fig. 7G) and furin (Fig. 7H) by ELISA with cell lysates at 8 DIV showed a 20-30% increase following CBL treatment (Figs. 7G, H) . In conclusion, CBL might enhance the survival of grafted NSC via furin mediated BDNF processing.
Discussion
The present study showed that CBL treatment enhanced the survival of grafted NSCs in APP tg mice. In contrast, in the vehicle-treated group there was decreased survival of transplanted neuroblasts that was worse in the APP tg mice. This is consistent with studies showing that the toxic microenvironment in the brain of APP tg mice might compromise the survival of both endogenous and transplanted NSCs. For example, a recent study showed that oligomerized Aβ42 promoted the expression of senescence-associated biomarkers p16 and senescence-associated β-galactosidase (SA-β-gal) in adult mouse hippocampal NSCs, and reduced the proliferation and differentiation of these cells in vitro and in APP/PS1 tg mice (He et al., 2013) . Moreover, we have observed that extracellular Aβ triggers apoptosis of transplanted NSCs and that genetically modified NSCs expressing neprilysin reduces amyloid load in APP tg mice and enhances the survival of NSCs and adjacent host neurons (Blurton-Jones et al., 2014) , supporting the view of beneficial effects of combined therapy with stem cells.
Previous studies have shown that transfer of rodent NSC into the hippocampus of APP/PS1 tg mice reduces behavioral deficits without changing amyloid β burden (Zhang et al., 2014a) and transplantation of NSCs derived from human iPSC reduce memory deficits in APP mice (Fujiwara et al., 2013 ).
More recent studies have utilized mesenchymal stem cells and shown CNS trafficking (Danielyan et al., 2014) and neurogenesis (Yan et al., 2014) in APP tg mice. Moreover, other studies have shown that NSC grafting reduced hippocampal Tau and reelin accumulation in aged Ts65Dn Down syndrome mice (Kern et al., 2011) and increased synaptic density in APP tg mice (Blurton-Jones et al., 2009; Zhang et al., 2014b) . Together, these studies support the notion that transfer of stem cells is beneficial by promoting neurogenesis and synaptogenesis of endogenous neuronal circuitries. In agreement with these studies, we found that combined NSC and CBL treatment was associated with endogenous neurogenesis and reduced degeneration of the hippocampal dentate gyrus in the APP tg mice.
However, it should be noted that while in previous studies the beneficial effects of stem cell monotherapy were noticed a few weeks post-transplant in our study the combined use of NSC with CBL continued to be helpful after a long period of time. As recently noted, poor viability of transplanted cells could be an important problem associated with stem cellbased therapy for PD (Nakaji-Hirabayashi et al., 2013) and other neurodegenerative disorders. For example, a recent study showed that combining a collagen hydrogel incorporating an integrin-binding protein complex as a carrier for neural stem cells improve the viability after transplantation into the striatum (Nakaji-Hirabayashi et al., 2013) . Similarly, it has been shown that co-transplantation of GDNF-overexpressing NSCs and fetal neurons ameliorates the motor deficits in a rat model of PD (Deng et al., 2013) . Along these lines, for the present study we combined the NSC graft with adjuvant therapy with CBL in an effort to enhance the survival of the transplanted cells. The mechanisms through which CBL might enhance the survival of the grafted cells are not completely clear. One possibility is that CBL might reduce the accumulation of toxic Aβ species that can potentially damage the grafted NSC. In agreement with this we showed lower levels of Aβload following 6 and 9 months of CBL treatment. Moreover previous studies have shown that CBL reduces Aβ production by reducing maturation of APP mediated by CDK5 and GSK3β activation (Rockenstein et al., 2006) . In addition, we showed that CBL increased furin levels, which in turn resulted in increased processing of pro-BDNF into BDNF in the grafted cells. This is consistent with previous studies showing that CBL might increase levels of NGF perhaps involving the processing of pro-NGF to its mature form (Ubhi et al., 2013) . The observed increase in furin levels in CBL-treated APP tg mice is consistent with this hypothesis.
Like pro-NGF (Fahnestock et al., 2001; Peng et al., 2004 ) pro-BNDF is the precursor protein of BDNF, which is abundant in the hippocampus (Barker, 2009; Bekinschtein et al., 2014; Lessmann and Brigadski, 2009; West et al., 2014) . Pro-BDNF undergoes cleavage by a family of mammalian processing enzymes, including furin (Chen et al., 2015; Fugere and Day, 2005; Seidah and Chretien, 1999) . To date there are nine known convertases (Fugere and Day, 2005; Seidah and Chretien, 1999) with furin being the most documented. Moreover, the furin recognition site has been reported to be essential for the proper processing of pro-BDNF to the mature form of BDNF (Lim et al., 2007) . Previous studies showed that NSCs are capable of producing BDNF that in turn can protect neighboring host cells (Blurton-Jones et al., 2009; Zhang et al., 2014b) . The neuropathological analysis showed that CBL reduced TUNEL and activated caspase-3 in the grafted NSCs, but had no effect of PCNA or Ki-67 at the later time points, supporting the notion of a trophic factor mediated anti-apoptotic effect. However, it is possible that other mechanisms might be at play, including a limited proliferative effect soon after transplantation.
In summary, the results of the present study suggest that CBL is capable of protecting the grafted NSC in an APP tg mouse model and as such be a potential adjuvant therapy when combined with cell based therapy.
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